Sonya Khan, M.D.
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
In the News
Present Title & Affiliation
Primary Appointment
Deputy Department Chair Ad Interim, Clinical Affairs, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas
Center Medical Director, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2006 | The University of Texas Medical Branch, Galveston, Texas, US, MD |
| 2001 | University of Houston, Houston, Texas, US, Biology, BS |
Postgraduate Training
| 2009-2011 | Clinical Fellowship, Endocrinology, University of Texas Health Science Center, Houston, Texas |
| 2006-2009 | Clinical Residency, Internal Medicine, University of Texas Health Science Center, Houston, Texas |
Licenses & Certifications
| 2026 | Stronger Together Diabetes Care in Cancer Treatment Certification-Diabetes Education |
| 2025 | Stronger Together Diabetes Care in Cancer Treatment |
| 2025 | Inpatient Advanced Inpatient Diabetes Joint Commission Certification for Disease Specific Certification |
| 2024 | Leadership Institute Leading Teams Core Cohort |
| 2024 | Texas Medical Board |
| 2022 | Texas Medical Board |
| 2021 | Endocrinology, Diabetes and Metabolism - American Board of Internal Medicine, MOC Certified |
| 2011 | Endocrinology, Diabetes and Metabolism - American Board of Internal Medicine, MOC Certified |
| 2010 | Texas Medical Board License |
| 2009 | Internal Medicine - American Board of Internal Medicine |
| 2009 | Internal Medicine - American Board of Internal Medicine |
| null | Oklahoma State Board of Medical Licensure |
| null | Alabama Board of Medical Examiners |
| null | Washington State Department of Health |
| null | Georgia Composite Medical Board |
| null | Louisiana State Board of Medical Examiners |
| null | Mississippi State Board of Medical Licensure |
| null | Tennessee Board of Medical Examiners |
| null | Arizona Board of Medical Examiners |
| null | Florida Board of Medicine |
Experience & Service
Administrative Appointments/Responsibilities
Center Medical Director, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Leading Teams Core Cohort, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - 2025
Associate Center Medical Director, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2024
Other Professional Positions
Palsonify Advisory Board, Crinetics Pharmaceuticals (United States), San Diego, California, 2026
Korlym Advisory Board, Corcept Therapeutics (United States), Menlo Park, California, 2024
Clinical Assistant Professor, University of Texas Medical Branch, Galveston, TX, 2019 - 2021
Endocrinologist, Clear Lake Specialties, Webster, TX, 2017 - 2021
Endocrinologist, Methodist Primary Care Group, Pearland, TX, 2014 - 2017
Endocrinologist, Christus Provider Network, Houston, TX, 2011 - 2014
Extramural Institutional Committee Activities
Officer, Endocrine Center Patient Experience, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Leadership Circle-Work Life Integration, The University of Texas MD Anderson Cancer Center, 2023 - 2024
Member, OPACC committee (outpatient ambulatory committee), The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Ambulatory Informatics Committee-, The University of Texas MD Anderson Cancer Center, 2023 - 2025
Member, DOIM education committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Pharmacy Treatment and Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2025
Member, Glycemic management GLYCAT committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Junior Faculty Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2025
Organizing Member, Multidisciplinary Conference; ENT, Endocrine, Nuclear Medicine, and Pathology, Christus St John Hospital, 2010 - 2017
Honors & Awards
| 2025 - 2026 | Top 10% nationally in clinician and group consumer assessment of healthcare providers and systems |
| 2024 - 2025 | Top 10% Nationally in clinician and group consumer assessment of healthcare providers and systems |
| 2023 - 2024 | Top 1% Diabetes and Cancer Education Booklet-National Health Information Silver Award |
| 2023 - 2024 | Perfect Score Nationally in clinician and group consumer assessment of healthcare providers and systems |
| 2022 - 2023 | Top 10% Nationally in clinician and group consumer assessment of healthcare providers and systems |
| 2021 - 2022 | Top 10% Nationally in clinician and group consumer assessment of healthcare providers and systems |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Steroid Induced Hyperglycemia. Invited. Clinical and Research Conference. Houston, Texas, US.
- 2025. “To Medicine or Not to Medicine. My Journey into Medicine”. Invited. Seven Lakes High School. Katy, Texas, US.
- 2025. Special Population in the Oncology Setting: TPN, Tube Feeds, and Steroids. Invited. Diabetes Lecture Series. Houston, Texas, US.
- 2024. Inpatient glycemic management at MD Anderson Cancer Center. Conference. Clinical and Research Conference. Houston, Texas, US.
- 2023. Insulin Administration in Special Populations: diabetes and insulin therapy, steroid induced hyperglycemia, patients s/p total pancreatectomy, patient on TPN and tube feeding. Conference. Insulin Administration in Special Populations: diabetes and insulin therapy, steroid induced hyperglycemia, patients s/p total pancreatectomy, patient on TPN and tube feeding. Houston, TX, US.
- 2021. Diabetes Case Presentation. Conference. Diabetes Case Presentation. Houston, TX, US.
- 2021. Diabetes Technology. Conference. Diabetes Technology. Houston, TX, US.
- 2021. Inpatient Hyperglycemia Management of Cancer Patients. Conference. Inpatient Hyperglycemia Management of Cancer Patients. Houston, TX, US.
- 2021. SGLT2 Inhibitors and Alerts. Conference. SGLT2 Inhibitors and Alerts. Houston, TX, US.
- 2021. SGLT2 inhibitors and Alerts. Conference. SGLT2 inhibitors and Alerts. Houston, TX, US.
- 2013. Muffin Tops and Metabolism - Metabolic Syndrome. Conference. Muffin Tops and Metabolism - Metabolic Syndrome. Houston, TX, US.
- 2012. What’s your Kryptonite superwoman?. Conference. What’s your Kryptonite superwoman?. Houston, TX, US.
- 2011. Why Am I So Tired?. Conference. Why Am I So Tired?. Houston, TX, US.
National Presentations
- 2026. Hypoparathyroidism: Acute and Chronic Management. Panelist. AAES Annual Meeting. Lexington, Kentucky, US.
- 2026. Controversies and Decision Making in Parathyroid Disease. Panelist. SSO Parathyroid Webinar, US.
- 2025. Immunotherapy Induced Endocrinopathies. Invited. TXEA/TESS 2025 Annual Meeting. San Antonio, Texas, US.
- 2025. Utilization of Decision Support Tool for Subcutaneous Insulin Dosing During ICU Insulin Infusion Transition. Poster. AACE 2025. Orlando, Florida, US.
- 2024. Hyperglycemia in a Novel CDK2 and CDK9 inhibitor-Fadraciclib. Conference. Case Presentation. New Orleans, LA, US.
- 2024. Hyper Warburg Effect and Hypoglycemia. Conference. Poster Presentation. New Orleans, LA, US.
- 2023. Hypercalcemia of Malignancy and Denosumab Withdrawal. Conference. Case Presentation, HI, US.
International Presentations
- 2025. Anti-obesity drugs and thyroid cancer. Invited. 28th International Thyroid Cancer Survivors' Conference. Houston, US.
- 2024. Anti-Obesity Medications and the Thyroid Cancer Connection. Invited. 27th International Thyroid Cancer Survivors' Conference. Houston, US.
Formal Peers
- 2026. Pituitary: Prolactinomas and Acromegaly. Houston, Texas, US.
- 2026. Steroid-Induced Hyperglycemia in the Oncology and Diabetes Population. Houston, Texas, US.
- 2025. Insulin administration in special populations. Houston, Texas, US.
- 2024. SGLT2 inhibitors and the Kidney. Houston, Texas, US.
- 2023. Insulin Administration in Special Populations: diabetes and insulin therapy, steroid induced hyperglycemia, patients s/p total pancreatectomy, patients on TPN and tube feeding. Visiting. Houston, TX, US.
- 2013. Radiation Induced Hypothyroidism. Visiting. Houston, TX, US.
- 2013. Diabetes: The Leading Epidemic in Seniors. Invited. Texas City, TX, US.
- 2010. Searching for the Thyroid. Invited. Houston, TX, US.
Selected Publications
Peer-Reviewed Articles
- Donovan D, Highsmith E, Herre M, Khan S. ICU Decision Tool Impact on Rebound Hyperglycemia. Advances in Cancer Education and Quality Improvement 2(1), 2026. e-Pub 2026.
- Gandhi, A, Jeun, R, Wang, Z, Khan, S, Best, CJ, Lavis, VR, Thosani, S. Etiologies and Outcomes of Diabetic Ketoacidosis in Cancer Patients. Cancers 17(17), 2025. e-Pub 2025. PMID: 40940823.
- Jayan A, Sukumar JS, Fangman B, Patel T, Raghavendra AS, Liu D, Pasyar S, Rauch R, Basen-Engquist K, Tripathy D, Wang Y, Khan SS, Barcenas CH. Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab. JCO Oncol Pract 21(9):1265-1273, 2025. e-Pub 2025. PMID: 39388649.
Review Articles
- Iyer PC, Kikani N, Khan S, Chaudhri A, Pagnotti G, Best C, Weitzman S, Mehta P, Lavis V, Thosani S, Gandhi A, Aguirre RS, Varghese J, Guise T, Dadu R. The evolving management of endocrine disorders induced by checkpoint inhibitors: insights from the CIITED group. Expert Rev Endocrinol Metab 21(1):1-13, 2025. e-Pub 2025. PMID: 41307239.
- Crouch, A, Chaudhri, AN, Khan, S, Ma, M, Vu, N, Towers, W. Acute Management of Hypercalcemia of Malignancy – A Review of Pathophysiology, Diagnosis, and Treatment. Current oncology reports 27(7):871-882, 2025. e-Pub 2025. PMID: 40434677.
Other Articles
- Khan S “Sweet Success: Implementation of an institution-wide glycemic management initiative”. DOIM Quality Improvement Research Retreat and Poster Session.
Abstracts
- Gandhi A, Jeun R, Khan S, Best C, Lavis VR, Thosani S. SUN-589 Diabetic Ketoacidosis in Cancer Patients: Etiological Patterns in a Tertiary Care Center. JES 9(1), 2025. e-Pub 2025.
- Gandhi, A, Jeun, R, Khan S, Best, C, Lavis, VR, Thosani, S. Diabetic Ketoacidosis in Cancer Patients: Etiological Patterns in a Tertiary Care Center. Endocrine Society 9(1), 2025. e-Pub 2025.
- Donovan D, Highsmith E, Khan S, Thosani S, Horng M. Impact of Decision Support Tool on ICU Rebound Hyperglycemia. TXEA/TESS Annual Meeting 2025. e-Pub 2025.
- Khan S, Monroy, A. Fadraciclib: A case report on severe hyperglycemia after initiation of this cancer therapy in relation with CDK2 activity. Inaugural Cancer Nursing Conference: Transforming Cancer Nursing Care through Quality Improvement, Evidence‑Based Practice, and Research. e-Pub 2025.
- Khan S, Monroy A, Brady V, Thosani S, Kikani N. Hyperglycemia in a Novel CDK2 and CDK9 inhibitor-Fadraciclib. AACE 2024.
- Khan S. Hyper Warburg Effect and Hypoglycemia. AACE 2024.
- Monroy Angela, Khan S. Hyperglycemia in a Novel CDK2 and CDK9 inhibitor-Fadraciclib. Transforming Cancer Nursing Care through Quality Improvement, Evidence Based Practice, and Research.
- Khalid S, Grubbs E, Skefos CM, Hu MI, Dadu R, Jimenez C, Ying AK, Sherman S, Toruner GA, Zafereo ME, Best C, Khan S, Iyer PC, Castellanos LE, Perrier ND, Waguespack SG. SAT-296 - MEN2A Secondary to the RET P.K666N Pathogenic Variant: Phenotype Expression in an Increasingly Diagnosed Disease. Endo Society.
Book Chapters
- Thosani, S, Salgado, SA, Khan S, Chaudhri, AN, Horng, M, Patel, M. Thyroid and Hyperglycemic Critical Care. In: The Oncologic Critical Care Textbook. Springer International Publishing, 2026.
- Thosani S, Khan S, Varghese J. Endocrine and Metabolic Complications of Cancer Therapy. In: The MD Anderson Manual of Medical Oncology. Fifth. McGraw Hill.
Web Publications
- Khan S. 6 tips to lower your blood sugar, 2026.
Patient Reviews
CV information above last modified September 02, 2026